Behavioral phenotyping of v-akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics

Neuroscience

Volumn 174, Issue , 2011, Pages 178-189

  Chen, Y W ^a   Lai, W S ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Akt1 knockout mice; Antipsychotics; Behavioral phenotyping; Neuromorphology of layer V pyramidal neurons; Prepulse inhibition; Schizophrenia

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CLOZAPINE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GREEN FLUORESCENT PROTEIN; NEUROLEPTIC AGENT; PROTEIN KINASE B; RACLOPRIDE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDITORY CORTEX; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; DOSE RESPONSE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LOCALIZATION; EXPERIMENTAL TEST; FEMALE; GENOTYPE; IMMOBILIZATION; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; TASK PERFORMANCE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; AUDITORY CORTEX; CLOZAPINE; DENDRITES; FEAR; FEMALE; GLYCOGEN SYNTHASE KINASE 3; INDOLES; MALE; MALEIMIDES; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; PYRAMIDAL CELLS; RACLOPRIDE; SEX FACTORS; STARTLE REACTION;

EID: 78650941147     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.09.056     Document Type: Article

References (52)

1. Aleman A., Kahn R.S., Selten J.P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003, 60:565-571.
2. Bajestan S.N., Sabouri A.H., Nakamura M., Takashima H., Keikhaee M.R., Behdani F., Fayyazi M.R., Sargolzaee M.R., Bajestan M.N., Sabouri Z., Khayami E., Haghighi S., Hashemi S.B., Eiraku N., Tufani H., Najmabadi H., Arimura K., Sano A., Osame M. Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:383-386.
3. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
4. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
5. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
6. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004, 101:5099-5104.
7. Bowen G.P., Lin D., Taylor M.K., Ison J.R. Auditory cortex lesions in the rat impair both temporal acuity and noise increment thresholds, revealing a common neural substrate. Cereb Cortex 2003, 13:815-822.
8. Braff D.L., Light G.A., Ellwanger J., Sprock J., Swerdlow N.R. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry 2005, 57:817-820.
9. Brody S.A., Conquet F., Geyer M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 2004, 172:187-195.
10. Campbell L.E., Hughes M., Budd T.W., Cooper G., Fulham W.R., Karayanidis F., Hanlon M.C., Stojanov W., Johnston P., Case V., Schall U. Primary and secondary neural networks of auditory prepulse inhibition: a functional magnetic resonance imaging study of sensorimotor gating of the human acoustic startle response. Eur J Neurosci 2007, 26:2327-2333.
11. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999, 96:8745-8750.
12. Cho H., Thorvaldsen J.L., Chu Q., Feng F., Birnbaum M.J. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001, 276:38349-38352.
13. Del'Guidice T., Beaulieu J.M. [Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses]. Med Sci (Paris) 2010, 26:647-651.
14. Dorph-Petersen K.A., Delevich K.M., Marcsisin M.J., Zhang W., Sampson A.R., Gundersen H.J.G., Lewis D.A., Sweet R.A. Pyramidal neuron number in layer 3 of primary auditory cortex of subjects with schizophrenia. Brain Res 2009, 1285:42-57.
15. Dulawa S.C., Gross C., Stark K.L., Hen R., Geyer M.A. Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition. Neuropsychopharmacology 2000, 22:650-659.
16. Duncan G.E., Moy S.S., Lieberman J.A., Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 2006, 184:190-200.
17. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 2004, 36:131-137.
18. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
19. Floody O.R., Ouda L., Porter B.A., Kilgard M.P. Effects of damage to auditory cortex on the discrimination of speech sounds by rats. Physiol Behav 2010, 101:260-268.
20. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
21. Gavrilescu M., Rossell S., Stuart G.W., Shea T.L., Innes-Brown H., Henshall K., McKay C., Sergejew A.A., Copolov D., Egan G.F. Reduced connectivity of the auditory cortex in patients with auditory hallucinations: a resting state functional magnetic resonance imaging study. Psychol Med 2010, 40:1149-1158.
22. Gogos A., Bogeski M., van den Buuse M. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behav Pharmacol 2008, 19:548-561.
23. Grigoriadis S., Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 2002, 47:437-442.
24. Hafner H., an der Heiden W., Behrens S., Gattaz W.F., Hambrecht M., Loffler W., Maurer K., Munk-Jorgensen P., Nowotny B., Riecher-Rossler A., Stein A. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull 1998, 24:99-113.
25. Hubl D., Koenig T., Strik W.K., Garcia L.M., Dierks T. Competition for neuronal resources: how hallucinations make themselves heard. Br J Psychiatry 2007, 190:57-62.
26. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Inada T., Ozaki N. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry 2004, 56:698-700.
27. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Ozaki N. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int J Neuropsychopharmacol 2006, 9:77-81.
28. Ikeda M., Yamanouchi Y., Kinoshita Y., Kitajima T., Yoshimura R., Hashimoto S., O'Donovan M.C., Nakamura J., Ozaki N., Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
29. Karege F., Perroud N., Schürhoff F., Méary A., Marillier G., Burkhardt S., Ballmann E., Fernandez R., Jamain S., Leboyer M., La Harpe R., Malafosse A. Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder. Genes Brain Behav 2010, 9:503-511.
30. Lai W.S., Xu B., Westphal K.G.C., Paterlini M., Olivier B., Pavlidis P., Karayiorgou M., Gogos J.A. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A 2006, 103:16906-16911.
31. Lee K., Joo E., Jeong S.H., Kang U., Roh M., Kim S., Song J., Hwang J., Kim S., Lee N., Ahn Y.M., Kim Y. No association between AKT1 polymorphism and schizophrenia: A case-control study in a Korean population and a meta-analysis. Neurosci Res 2010, 66:238-245.
32. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo] regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
33. Liu Y.L., Fann C.S.J., Liu C.M., Wu J.Y., Hung S.I., Chan H.Y., Chen J.J., Pan C.C., Liu S.K., Hsieh M.H., Hwang T.J., Ouyang W.C., Chen C.Y., Lin J.J., Chou F.H.C., Chueh C.M., Liu W.M., Tsuang M.M., Faraone S.V., Tsuang M.T., Chen W.J., Hwu H.G. Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population. Psychiatr Genet 2006, 16:39-41.
34. McGrath J.J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004, 2:13.
35. Meijer L., Flajolet M., Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004, 25:471-480.
36. Miller J., Tallarida R., Unterwald E. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2009, 56:1116-1123.
37. Norton N., Williams H.J., Dwyer S., Carroll L., Peirce T., Moskvina V., Segurado R., Nikolov I., Williams N.M., Ikeda M., Iwata N., Owen M.J., O'Donovan M.C. Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res 2007, 93:58-65.
38. Norton N., Williams H.J., Owen M.J. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006, 19:158-164.
39. Ohtsuki T., Inada T., Arinami T. Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol Psychiatry 2004, 9:981-983.
40. Pelloux Y., Hagues G., Costentin J., Duterte-Boucher D. Helplessness in the tail suspension test is associated with an increase in ethanol intake and its rewarding effect in female mice. Alcohol Clin Exp Res 2005, 29:378-388.
41. Rabinowicz E.F., Silipo G., Goldman R., Javitt D.C. Auditory sensory dysfunction in schizophrenia: imprecision or distractibility?. Arch Gen Psychiatry 2000, 57:1149-1155.
42. Read D.E., Gorman A.M. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci 2009, 66:2975-2984.
43. Salokangas R.K.R., Honkonen T., Saarinen S. Women have later onset than men in schizophrenia-but only in its paranoid form. Results of the DSP project. Eur Psychiatry 2003, 18:274-281.
44. Scheid M.P., Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001, 2:760-768.
45. Schwab S.G., Hoefgen B., Hanses C., Hassenbach M.B., Albus M., Lerer B., Trixler M., Maier W., Wildenauer D.B. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry 2005, 58:446-450.
46. Schwab S.G., Wildenauer D.B. Update on key previously proposed candidate genes for schizophrenia. Curr Opin Psychiatry 2009, 22:147-153.
47. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156:194-215.
48. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 2006, 63:1325-1335.
49. Tan H.Y., Nicodemus K.K., Chen Q., Li Z., Brooke J.K., Honea R., Kolachana B.S., Straub R.E., Meyer-Lindenberg A., Sei Y., Mattay V.S., Callicott J.H., Weinberger D.R. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008, 118:2200-2208.
50. Thiselton D.L., Vladimirov V.I., Kuo P.H., McClay J., Wormley B., Fanous A., O'Neill F.A., Walsh D., Van den Oord E.J.C.G., Kendler K.S., Riley B.P. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry 2008, 63:449-457.
51. Xu M.Q., Xing Q.H., Zheng Y.L., Li S., Gao J.J., He G., Guo T.W., Feng G.Y., Xu F., He L. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007, 68:1358-1367.
52. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006, 84:1-14.